ClinicalTrials.gg
CompletedNCT03164070Updated Jan 9, 2019

Study of the Laboratory-based Evaluation of the Degrees of Activity of Osteoarthritis

An observational study in Osteoarthritis, sponsored by The Republican Research and Practical Center for Epidemiology and Microbiology. Completed at 1 site in Belarus. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by The Republican Research and Practical Center for Epidemiology and Microbiology · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
121
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study evaluates laboratory-based method to estimate the degrees of activity of medium and large joint osteoarthritis.

Read the detailed description

Osteoarthritis (OA) is a chronic progressive disease, characterized by degradation of joint cartilage, synovial inflammation and joint dysfunction. This study evaluates laboratory-based method to estimate the degrees of activity of medium and large joint OA. Samples of synovial fluid (SF) from the patients with the OA (ICD-10 codes: M15, M16 and M17) will be assessed for T-cell subsets, msast cells, fibroblast-like synoviocytes (FLS) and macrophage-like synoviocytes (MLS) by flow cytometry. Subpopulations of blood T-cells involved in the inflammation will also be assayed. Standard clinical investigation will be performed and the results will be used to estimate the laboratory criteria or degrees of activity of medium and large joint OA.

02

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis
  • Flow cytometry
  • Synovial fluid
03

In context

Osteoarthritis

2,974 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's enrollment of 121 is above the median of 100 across 601 observational studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

The Republican Research and Practical Center for Epidemiology and Microbiology is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with medium and large joint osteoarthritis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • medium and large joint active osteoarthritis

Exclusion criteria

Exclusion Criteria:

  • refuse of patient to participate in the trial;
  • acute infectious diseases;
  • pregnancy/lactation;
  • intercurrent severe chronic diseases;
  • , Hepatites B/C;
  • active tuberculosis;
  • alcohol use disorder/drug addiction;
  • malignant neoplasms/leukemia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
121 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with osteoarthritis

    Patients with medium and large joint osteoarthritis

  • Control group

    Control group of healthy persons

06

What researchers measure

Primary outcomes

  1. The sensitivity of the proposed laboratory-based method in the diagnostics of the activity of osteoarthritis

    The sensitivity of the proposed laboratory-based method in the diagnostics of the activity of medium and large joint osteoarthritis

    Time frame: 2 month

07

Study locations

1 site
  • Andrei Hancharou
    Minsk, 220114, Belarus
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03164070
Lead sponsor
The Republican Research and Practical Center for Epidemiology and Microbiology
Collaborators
Belarusian Medical Academy of Post-Graduate Education
Responsible party
Andrei Y. Hancharou (Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology) — Principal investigator
First posted
May 23, 2017
Start date
Jul 1, 2016
Primary completion
Dec 10, 2018
Completion
Dec 29, 2018
Last update
Jan 9, 2019

Study contacts

Andrei Y Hancharou, Dr
study director · Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion